Anti-infliximab antibody concentrations can guide on treatment intensification in patients with Crohn's disease who lose clinical response

Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease

D'Haens, Geert
vander Woude, Janneke
Moreau, J.
Van Hootegem, Ph
Louis, Edouard
Franchimont, Denis
De Vos, Martine
Mana, Fazia
Peyrin-Biroulet, Laurent
Brixi, Hedia
Allez, Matthieu
Vermeire, Séverine
Caenepeel, Philippe
Aubourg, Alexandre
Oldenburg, Bas
Pierik, Marieke
Gils, Ann
Chevret, Sylvie
Laharie, David
Détré, Patricia
Bertin, Marie Jo
Williams, Sabrina
Lambrecht, Guy
Baert, Filip
Bossuyt, Peter
Pariente, Benjamin
Buisson, Anthony
Bouhnik, Yoram
Filippi, Jerome

April 2018

Background & Aims: A combination of infliximab and immunomodulators is the most efficacious treatmen...

Triantafillidis, J K
Mantzaris, G
Karagiannis, J
Papavasilliou, E
Papatheodoridis, G
Fouskas, J
Malgarinos, G
Gikas, A
Papamichael, Konstantinos
Mathou, Nicoletta
Symboulakis, E
Karamanolis, D

January 2010

The aim of this study was to investigate the efficacy of adalimumab, in patients with moderately act...

Clinical role, optimal timing and frequency of serum infliximab and anti-infliximab antibody level measurements in patients with inflammatory bowel disease.

Renáta Bor
Klaudia Farkas
Anna Fábián
Anita Bálint
Ágnes Milassin
Mariann Rutka
Mária Matuz
Ferenc Nagy
Zoltán Szepes
Tamás Molnár

January 2017

BACKGROUND:Serum infliximab (IFX) and antibody-to-infliximab (ATI) levels are objective parameters, ...

Anti-infliximab antibody concentrations can guide on treatment intensification in patients with Crohn's disease who lose clinical response

Dreesen, Erwin
Van Stappen, Thomas
Ballet, Vera
Peeters, Miet
Compernolle, Griet
Tops, Sophie
Van Steen, Kristel
Van Assche, Gert
Ferrante, Marc
Vermeire, Séverine
Gils, Ann

January 2018

The presence of antibodies towards infliximab (ATI) is associated with lower infliximab (IFX) trough...

Anti-infliximab antibody concentrations can guide treatment intensification in patients with Crohn's disease who lose clinical response

Dreesen, E.
Van Stappen, T.
Ballet, V.
Peeters, M.
Compernolle, G.
Tops, S.
Van Steen, Kristel
Van Assche, G.
Ferrante, M.
Vermeire, S.
Gils, A.

January 2018

Background: The presence of antibodies towards infliximab (ATI) is associated with lower infliximab ...

The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease

Vande Casteele, Niels
Khanna, Reena
Levesque, Barrett G
Stitt, Larry
Zou, GY
Singh, Sharat
Lockton, Steve
Hauenstein, Scott
Ohrmund, Linda
Greenberg, Gordon R
Rutgeerts, Paul
Gils, Ann
Sandborn, William J
Vermeire, Severine
Feagan, Brian G

October 2015

Although low infliximab trough concentrations and antibodies to infliximab (ATI) are associated with...

Efficacy of switching to infliximab in patients with Crohn's disease with loss of response to adalimumab

Peeters, H
Louis, E
Dewit, O
Coche, J C
Ferrante, Marc
Lambrecht, G
Colard, A
Van Gossum, Anna
Bossuyt, Peter
Moreels, T
Vander Cruyssen, B
Gils, Ann
De Vos, Marnik

March 2018

Anti-TNF monoclonal antibodies are a cornerstone in the treatment of Crohn's disease. Prospective da...

Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease.

Pariente, B
Pineton de Chambrun, G
Krzysiek, R
Desroches, M
Louis, G
DE CASSAN, Chiara
Baudry, C
Gornet, Jm
Desreumaux, P
Emilie, D
Colombel, Jf
Allez, M.

January 2012

Background: Infliximab is effective for the treatment of refractory inflammatory bowel disease (IBD)...

Trough Concentrations of Infliximab Guide Dosing for Patients with Inflammatory Bowel Disease

Vande Casteele, Niels
Ferrante, Marc
Van Assche, Gert
Ballet, Vera
Compernolle, Griet
Van Steen, Kristel
Simoens, Steven
Rutgeerts, Paul
Gils, Ann
Vermeire, Séverine

June 2015

Infliximab, a tumor necrosis factor antagonist, is effective for treating patients with Crohn's dise...

Less Anti-infliximab Antibody Formation in Paediatric Crohn Patients on Concomitant Immunomodulators

Kansen, H.M.
Rheenen, P.F. van
Houwen, R.H.
Tjon, A.T.M.R.
Damen, G.M.
Kindermann, A.
Escher, J.C.
Wolters, V.M.

January 2017

Item does not contain fulltextOBJECTIVES: To evaluate the effect of immunomodulators on formation of...

Combination of C-reactive Protein, Infliximab Trough Levels, and Stable but Not Transient Antibodies to Infliximab Are Associated With Loss of Response to Infliximab in Inflammatory Bowel Disease

Roblin, X.
Marotte, H.
Leclerc, M.
del Tedesco, E.
Phelip, J.M.
Peyrin-Biroulet, L.
Paul, S.

June 2015

International audienceBACKGROUND:Antibodies to infliximab [ATI] and trough levels to infliximab [TRI...

Withdrawal of Immunomodulators After Co-treatment Does not Reduce Trough Level of Infliximab in Patients with Crohn's Disease

Drobne, David
Bossuyt, Peter
Breynaert, Christine
Cattaert, Tom
Vande Casteele, Niels
Compernolle, Griet
Jürgens, Matthias
Ferrante, Marc
Ballet, Vera
Wollants, Willem-Jan
Cleynen, Isabelle
Van Steen, Kristel
Gils, Ann
Rutgeerts, Paul
Vermeire, Severine
Van Assche, Gert

March 2015

The addition of immunomodulators increases the efficacy of maintenance therapy with infliximab, for ...

Measuring infliximab and adalimumab drug and antibodies in Crohn's disease and ulcerative colitis

August 2020

The anti-TNF therapies infliximab and adalimumab have revolutionized the treatment of inflammatory b...

Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, or Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease

D'Haens, Geert
Vermeire, Severine
Lambrecht, Guy
Baert, Filip
Bossuyt, Peter
Pariente, Benjamin
Buisson, Anthony
Bouhnik, Yoram
Filippi, Jérôme
Vander Woude, Janneke
van Hootegem, Philippe
Moreau, Jacques
Louis, Edouard
Franchimont, Denis
de Vos, Martine
Mana, Fazia
Peyrin-Biroulet, Laurent
Brixi, Hedia
Allez, Matthieu
Caenepeel, Philip
Aubourg, Alexandre
Oldenburg, Bas
Pierik, Marieke
Gils, Ann
Chevret, Sylvie
Laharie, David

January 2018

A combination of infliximab and immunomodulators is the most efficacious treatment for Crohn's disea...

Serum Levels of Infliximab and Anti-Infliximab Antibodies in Brazilian Patients with Crohn’s Disease

Luis Eduardo Miani Gomes
Francesca Aparecida Ramos da Silva
Lívia Bitencourt Pascoal
Renato Lazarin Ricci
Guilherme Nogueira
Michel Gardere Camargo
Maria de Lourdes Setsuko Ayrizono
João José Fagundes
Raquel Franco Leal

April 2019

OBJECTIVES: The aim of this study was to evaluate the quantitative serum level of infliximab (IFX) a...

Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease

D'Haens, Geert
vander Woude, Janneke
Moreau, J.
Van Hootegem, Ph
Louis, Edouard
Franchimont, Denis
De Vos, Martine
Mana, Fazia
Peyrin-Biroulet, Laurent
Brixi, Hedia
Allez, Matthieu
Vermeire, Séverine
Caenepeel, Philippe
Aubourg, Alexandre
Oldenburg, Bas
Pierik, Marieke
Gils, Ann
Chevret, Sylvie
Laharie, David
Détré, Patricia
Bertin, Marie Jo
Williams, Sabrina
Lambrecht, Guy
Baert, Filip
Bossuyt, Peter
Pariente, Benjamin
Buisson, Anthony
Bouhnik, Yoram
Filippi, Jerome

April 2018

Background & Aims: A combination of infliximab and immunomodulators is the most efficacious treatmen...

Triantafillidis, J K
Mantzaris, G
Karagiannis, J
Papavasilliou, E
Papatheodoridis, G
Fouskas, J
Malgarinos, G
Gikas, A
Papamichael, Konstantinos
Mathou, Nicoletta
Symboulakis, E
Karamanolis, D

January 2010

The aim of this study was to investigate the efficacy of adalimumab, in patients with moderately act...

Clinical role, optimal timing and frequency of serum infliximab and anti-infliximab antibody level measurements in patients with inflammatory bowel disease.

Renáta Bor
Klaudia Farkas
Anna Fábián
Anita Bálint
Ágnes Milassin
Mariann Rutka
Mária Matuz
Ferenc Nagy
Zoltán Szepes
Tamás Molnár

January 2017

BACKGROUND:Serum infliximab (IFX) and antibody-to-infliximab (ATI) levels are objective parameters, ...

Anti-infliximab antibody concentrations can guide on treatment intensification in patients with Crohn's disease who lose clinical response

Dreesen, Erwin
Van Stappen, Thomas
Ballet, Vera
Peeters, Miet
Compernolle, Griet
Tops, Sophie
Van Steen, Kristel
Van Assche, Gert
Ferrante, Marc
Vermeire, Séverine
Gils, Ann

January 2018

The presence of antibodies towards infliximab (ATI) is associated with lower infliximab (IFX) trough...

Anti-infliximab antibody concentrations can guide treatment intensification in patients with Crohn's disease who lose clinical response

Dreesen, E.
Van Stappen, T.
Ballet, V.
Peeters, M.
Compernolle, G.
Tops, S.
Van Steen, Kristel
Van Assche, G.
Ferrante, M.
Vermeire, S.
Gils, A.

January 2018

Background: The presence of antibodies towards infliximab (ATI) is associated with lower infliximab ...

The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease

Vande Casteele, Niels
Khanna, Reena
Levesque, Barrett G
Stitt, Larry
Zou, GY
Singh, Sharat
Lockton, Steve
Hauenstein, Scott
Ohrmund, Linda
Greenberg, Gordon R
Rutgeerts, Paul
Gils, Ann
Sandborn, William J
Vermeire, Severine
Feagan, Brian G

October 2015

Although low infliximab trough concentrations and antibodies to infliximab (ATI) are associated with...

Efficacy of switching to infliximab in patients with Crohn's disease with loss of response to adalimumab

Peeters, H
Louis, E
Dewit, O
Coche, J C
Ferrante, Marc
Lambrecht, G
Colard, A
Van Gossum, Anna
Bossuyt, Peter
Moreels, T
Vander Cruyssen, B
Gils, Ann
De Vos, Marnik

March 2018

Anti-TNF monoclonal antibodies are a cornerstone in the treatment of Crohn's disease. Prospective da...

Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease.

Pariente, B
Pineton de Chambrun, G
Krzysiek, R
Desroches, M
Louis, G
DE CASSAN, Chiara
Baudry, C
Gornet, Jm
Desreumaux, P
Emilie, D
Colombel, Jf
Allez, M.

January 2012

Background: Infliximab is effective for the treatment of refractory inflammatory bowel disease (IBD)...

Trough Concentrations of Infliximab Guide Dosing for Patients with Inflammatory Bowel Disease

Vande Casteele, Niels
Ferrante, Marc
Van Assche, Gert
Ballet, Vera
Compernolle, Griet
Van Steen, Kristel
Simoens, Steven
Rutgeerts, Paul
Gils, Ann
Vermeire, Séverine

June 2015

Infliximab, a tumor necrosis factor antagonist, is effective for treating patients with Crohn's dise...

Less Anti-infliximab Antibody Formation in Paediatric Crohn Patients on Concomitant Immunomodulators

Kansen, H.M.
Rheenen, P.F. van
Houwen, R.H.
Tjon, A.T.M.R.
Damen, G.M.
Kindermann, A.
Escher, J.C.
Wolters, V.M.

January 2017

Item does not contain fulltextOBJECTIVES: To evaluate the effect of immunomodulators on formation of...

Combination of C-reactive Protein, Infliximab Trough Levels, and Stable but Not Transient Antibodies to Infliximab Are Associated With Loss of Response to Infliximab in Inflammatory Bowel Disease

Roblin, X.
Marotte, H.
Leclerc, M.
del Tedesco, E.
Phelip, J.M.
Peyrin-Biroulet, L.
Paul, S.

June 2015

International audienceBACKGROUND:Antibodies to infliximab [ATI] and trough levels to infliximab [TRI...

Withdrawal of Immunomodulators After Co-treatment Does not Reduce Trough Level of Infliximab in Patients with Crohn's Disease

Drobne, David
Bossuyt, Peter
Breynaert, Christine
Cattaert, Tom
Vande Casteele, Niels
Compernolle, Griet
Jürgens, Matthias
Ferrante, Marc
Ballet, Vera
Wollants, Willem-Jan
Cleynen, Isabelle
Van Steen, Kristel
Gils, Ann
Rutgeerts, Paul
Vermeire, Severine
Van Assche, Gert

March 2015

The addition of immunomodulators increases the efficacy of maintenance therapy with infliximab, for ...

Measuring infliximab and adalimumab drug and antibodies in Crohn's disease and ulcerative colitis

August 2020

The anti-TNF therapies infliximab and adalimumab have revolutionized the treatment of inflammatory b...

Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, or Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease

D'Haens, Geert
Vermeire, Severine
Lambrecht, Guy
Baert, Filip
Bossuyt, Peter
Pariente, Benjamin
Buisson, Anthony
Bouhnik, Yoram
Filippi, Jérôme
Vander Woude, Janneke
van Hootegem, Philippe
Moreau, Jacques
Louis, Edouard
Franchimont, Denis
de Vos, Martine
Mana, Fazia
Peyrin-Biroulet, Laurent
Brixi, Hedia
Allez, Matthieu
Caenepeel, Philip
Aubourg, Alexandre
Oldenburg, Bas
Pierik, Marieke
Gils, Ann
Chevret, Sylvie
Laharie, David

January 2018

A combination of infliximab and immunomodulators is the most efficacious treatment for Crohn's disea...

Serum Levels of Infliximab and Anti-Infliximab Antibodies in Brazilian Patients with Crohn’s Disease

Luis Eduardo Miani Gomes
Francesca Aparecida Ramos da Silva
Lívia Bitencourt Pascoal
Renato Lazarin Ricci
Guilherme Nogueira
Michel Gardere Camargo
Maria de Lourdes Setsuko Ayrizono
João José Fagundes
Raquel Franco Leal

April 2019

OBJECTIVES: The aim of this study was to evaluate the quantitative serum level of infliximab (IFX) a...

Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease

D'Haens, Geert
vander Woude, Janneke
Moreau, J.
Van Hootegem, Ph
Louis, Edouard
Franchimont, Denis
De Vos, Martine
Mana, Fazia
Peyrin-Biroulet, Laurent
Brixi, Hedia
Allez, Matthieu
Vermeire, Séverine
Caenepeel, Philippe
Aubourg, Alexandre
Oldenburg, Bas
Pierik, Marieke
Gils, Ann
Chevret, Sylvie
Laharie, David
Détré, Patricia
Bertin, Marie Jo
Williams, Sabrina
Lambrecht, Guy
Baert, Filip
Bossuyt, Peter
Pariente, Benjamin
Buisson, Anthony
Bouhnik, Yoram
Filippi, Jerome

April 2018

Background & Aims: A combination of infliximab and immunomodulators is the most efficacious treatmen...

Triantafillidis, J K
Mantzaris, G
Karagiannis, J
Papavasilliou, E
Papatheodoridis, G
Fouskas, J
Malgarinos, G
Gikas, A
Papamichael, Konstantinos
Mathou, Nicoletta
Symboulakis, E
Karamanolis, D

January 2010

The aim of this study was to investigate the efficacy of adalimumab, in patients with moderately act...

Clinical role, optimal timing and frequency of serum infliximab and anti-infliximab antibody level measurements in patients with inflammatory bowel disease.

Renáta Bor
Klaudia Farkas
Anna Fábián
Anita Bálint
Ágnes Milassin
Mariann Rutka
Mária Matuz
Ferenc Nagy
Zoltán Szepes
Tamás Molnár

January 2017

BACKGROUND:Serum infliximab (IFX) and antibody-to-infliximab (ATI) levels are objective parameters, ...

Anti-infliximab antibody concentrations can guide on treatment intensification in patients with Crohn's disease who lose clinical response

Abstract

Extracted data

Anti-infliximab antibody concentrations can guide on treatment intensification in patients with Crohn's disease who lose clinical response

Abstract

Extracted data

Related items

Related items